Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the completion of the sale, the chief operating officer now owns 535,457 shares in the company, valued at $3,860,644.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Tina Marriott also recently made the following trade(s):
- On Thursday, May 30th, Tina Marriott sold 3,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.78, for a total transaction of $26,340.00.
- On Thursday, April 25th, Tina Marriott sold 3,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.67, for a total transaction of $23,010.00.
Recursion Pharmaceuticals Stock Performance
Shares of RXRX opened at $7.50 on Monday. The firm has a market cap of $1.78 billion, a PE ratio of -4.69 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.97 and a twelve month high of $16.75. The firm’s 50 day moving average price is $8.84 and its 200 day moving average price is $9.95.
Institutional Trading of Recursion Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter worth about $26,000. National Bank of Canada FI boosted its holdings in shares of Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after acquiring an additional 1,500 shares in the last quarter. First Horizon Advisors Inc. acquired a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $47,000. Oxford Wealth Group LLC acquired a new position in Recursion Pharmaceuticals in the first quarter worth $106,000. Finally, Daiwa Securities Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 1,508.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 11,759 shares of the company’s stock worth $116,000 after purchasing an additional 11,028 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have recently commented on RXRX. KeyCorp upped their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th. Needham & Company LLC reissued a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th.
Check Out Our Latest Research Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
- Five stocks we like better than Recursion Pharmaceuticals
- What Are Dividend Champions? How to Invest in the Champions
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Breakout Stocks: What They Are and How to Identify Them
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.